Emerging drugs in colorectal cancer

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 193-202

  Scott, Lucy ^a   Fraser, Judith ^a   Cassidy, Jim ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Emerging drugs; Novel agents

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BCG VACCINE; BETA CATENIN; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CEAVAC; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBITOX; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMC 225; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALTITREXED;

ADOPTIVE IMMUNOTHERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; ASTHENIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; META ANALYSIS; MUCOSA INFLAMMATION; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; RASH; REVIEW; STOMATITIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038318827     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.193     Document Type: Review

References (75)

1. CHU KC, TARONE RE, CHOW WH, et al.: Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J. Natl. Cancer Inst. (1994) 86:997-1006.
2. PARKIN DM, PISANI P, FERLAY J: Global cancer statistics. CA Cancer J. Clin. (1999) 49:33-64.
3. LANDIS SH, MURRAY T, BOLDEN S et al.: Cancer statistics 1999. CA Cancer J. Clin. (1999) 49:8-31.
4. MIDGLEY R, KERR D: Colorectal cancer. Lancet (1999) 353:391-399.
5. WILLIAMS NS, NORTHOVER JMA, ARNOTT SJ et al.: Colorectal tumours. In: Oxford Textbook of Oncology. Peckham M, Pinedo H, Veronesi U (Eds), Oxford University Press, Oxford, UK (1995):1133-1168.
6. BLIJHAM GH: Chemotherapy of colorectal cancer. Anticancer Drugs (1991) 2:233-245.
7. MAYER RJ: Chemotherapy for metastatic colorectal cancer. Cancer (1992) 70(5 Suppl.):1414-1424.
8. BENSON AB III: Therapy for advanced colorectal cancer. Semin. Oncol. (1998) 25(11 Suppl.):2-11.
9. CONLEY BA, KAPLAN RS, ARBUCK SG: National Cancer Institute Clinical Trials program in colorectal cancer. Cancer Chemother. Pharmacol. (1998) 42(Suppl.):S79-S79.
10. SCHEITHAUER W, ROSEN M, KERNECK GV et al.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. (1993) 306:752-755.
11. POON MA, O'CONNELL MJ, WIEAND HS et al.: Biochemical modulation of flourouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. (1991) 9:1967-1972.
12. META-ANALYSIS GROUP IN CANCER: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. (1998) 16:301-308. Important paper regarding 5-FU scheduling.
13. ROUGIER PH, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1407-1412.
14. IMPACT INVESTIGATORS: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet (1995) 345:934-228.
15. FRANCINI G, PETRIOLI R, LORENZINI L et al.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology (1994) 106:899-906.
16. O'CONNELL MJ, LAURIE JA, KAHN M: Prospectively randomised trial of post-operative adjuvant chemotherapy in patients with high risk colon cancer. J. Clin. Oncol. (1998) 16:295-300.
17. HALLER DG, CATALANO PJ, MACDONALD JS et al.: Fluorouracil (FU), leucovorin (LV) and levimasole (LEV) adjuvant therapy for colon cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:256a.
18. WOOLMARK N, ROCKETTE H, MAMOUNAS E et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levimasole, and fluorouracil, leucovorin and levimasole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. (1999) 17:3553-3559.
19. KERR DJ, GRAY R, MCCONKEY C, BARNWELL J: Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid for patients with colorectal cancer: non randomised comparison of weekly versus four weeldy schedules-less pain same gain. The Quasar Colorectal Cancer Study Group. Ann. Oncol. (2000) 11:947-955. Important paper reganting 5-FU scheduling.
20. DEMARIO MD, RATAIN MJ: Oral chemotherapy: rationale and future directions. J. Clin. Oncol. (1998) 16:2557-2567.
21. RUSTUM YM, MARSTRICK A, CAO S et al.: Thymidilate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. (1997) 15:389-400.
22. PUNT C: New drugs in the treatment of colorectal carcinoma. Cancer (1998) 83:679-689.
23. RON IG, LOTAN A, INBAR MJ et al.: Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs (1996) 7:649-654.
24. PAZDUR R, LASSERE Y, RHODES V et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol. (1994) 12:2296-2300.
25. PAZDUR R, DOUILLARD J-Y, SKILLINGS JR et al.: Multicenter phase III study of 5-fluorouracil (5-FU) of UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract 1009] Proc. Am. Soc. Clin. Oncol. (1999) 18:263a. Updated in September 1999 for regulatory filing to the US Food and Drug Administration.
26. CARMICHAEL J, POPIELA T, RADSTONE D: Randomised comparative study of ORZEL plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:1016 (Abstract).
27. MIWA M, URA M, NISHIDA M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues. Eur. J. Cancer (1998) 8:1274-1281.
28. ISHIKAWA T, SEKIGUCHI F, FUKASE Y et al.: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res. (1998) 58:685-690.
29. VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al.: Capecitabine (Xeloda™), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomised phase II study. J. Clin. Oncol. (2000) 18:1338-1345.
30. TWELVES C, BOYER M, FINDLAY M et al.: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur. J. Cancer (2001) 37(5):597-604. Good information regarding capecitabine.
31. HOFF PM, ANSAR R, BATIST G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer; results of a randomised phase III study. J. Clin. Oncol. (2001) 19(8):2282-2292. Good information regarding capecitabine.
32. LIU G, FRANSSEN E, FITCH M et al.: Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. (1997) 15:110-115.
33. BORNER M, SCHOFFSKI P, DE WIT R et al.: A randomised cross-over trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouradl (FU) + LV for patient preferences and pharmacokinetic studies in advanced colorectal cancer [abstract 741] Proc. Am. Soc. Clin. Oncol. (2000) 19:191a.
34. PAYNE SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. (1992) 35:1505-1509.
35. GUNASEKARA NS, FAULDS D: Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs (1998) 55:423-432.
36. COCCONI G, CUNNINGHAM D, VAN CUTSEM E et al.: Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. (1998) 16:2943-2952.
37. CUNNINGHAM D, ZALCBERG JR, RATH U et al.: Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol. (1996) 7:961-965.
38. PAZDUR R, VINCENT M: Raltitrexed (Tomudex) versus 5-flourouracil and leucovorin (5-FU + LV in patients with advanced colorectal cancer (ACC): results of a randomised, multi-center, North American trial (abstract 801). Proc. Am. Soc. Clin. Oncol. Annual. Meeting (1997) 16:228a.
39. MAUGHAN TS, JAMES RD, KERR D et al.: Preliminary results of a multi-center, randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich, and raltitrexed) in metastatic colorectal cancer (abstract 8). Proc. Am. Soc. Clin. Oncol. Annual Meeting (1999) 18:262a.
40. ROTHENBERG ML, COX JV, DE VORE RF et al.: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 85:786-795.
41. ROUGIER PH, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1407-1412.
42. CUNNINGHAM D, PYRHONEN S, JAMES RD et al.: Randomised trial of irinotecan Plus supportive care vs supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1413-1418. Excellent paper regarding chemotherapy versus best supportive care.
43. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet (2000) 355:1041-1047. Good irinotecan information.
44. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
45. ANDRE T, BENSMAINE MA, LOUVET C et al.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin Oncol. (1999) 17(11):3560-3568.
46. LEVI F, ZIDANI R, MISSET JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet (1997) 350(9079):681-686.
47. LEVI FA, ZIDANI R, VANNETZEL JM et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy by oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal metastases: a randomised multiinstitutional trial. J. Natl. Cancer Inst. (1994) 186(21):1608-1617.
48. GIACCHETTI S, PERPOINT B, ZIDANI R et al.: Phase III randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. (2000) 18:136-146. Important oxaliplatin trial.
49. DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and flourouracil, with or without, oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18(16):2938-2947. Important oxaliplatin trial.
50. POWELL SM, ZILZ N, BEAZER-BARCLAY Y et al.: APC mutations occur early during colorectal tumourigenesis. Nature (1992) 359:235-237.
51. KINZLER KW, VOGELSTEIN B: Lessons from hereditary colorectal cancer. Cell (1996) 87:159-170.
52. WATTERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. (2000) 18:1812-1823.
53. JANSEN B, WADL H, INOUE SA et al.: Phophorthioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res. Dev. (1995) 5:271-277.
54. MAYER A, TAKIMOTO M, FRITZ E et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 71:2454-2460.
55. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 20:7.
56. SALTZ L, MEROPOL N, LOEHRER P et al.: Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2002) 21:504.
57. GIBBS JB, OLIFF A, KOHL NE: Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell (1994) 77:175-178.
58. CASCINU S, STACCIOLI MP, GASPARINI G et al.: Expression of endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. (2000) 6:2803-2807.
59. BERGSLAND E, HURWITZ H, FEHRENBACHER L et al.: A randomised phase II trial comparing rhuMAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:242a (Abstract #939).
60. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase 2 randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/lv alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:1,60-65.
61. DEVORE R, FEHRENBACHER L, HERBST RS et al.: A randomised Phase 2 trial comparing rhuMAB VEGF (recombinant human monoclonal antibody) and carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:485a (Abstract #1896).
62. ZAKNOEN S, WOLFF R, COX J et al.: Marimastat in advanced progressive colorectal cancer: a dose finding study. Proc. Am. Soc. Clin. Oncol. (1997) 16:273a.
63. GIOVANNUCCI E, EGAN KM, HUNTER DJ et al.: Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. (1995) 333:609-614.
64. SMALLEY W, RAY WA, DAUGHERTY J et al.: Use of non-steroidal anti inflammatory drugs and the incidence of colorectal cancer. A population based study. Arch. Int. Med. (1999) 159:161-166.
65. SHEEHAN KM, STEAHAN K, O'DONAGHUE D et al.: The relationship between COX-2 expression and colorectal cancer. JAMA (1999) 282:1254-1257.
66. EBERHART CE, COFFEY RJ, RADHIKA A et al.: Upregulation of cycloxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 107:1183-1188.
67. OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in APC knockout mice by inhibition of COX-2. Cell (1996) 87:803-809.
68. STEINBACH G, LYNCH PM, PHILIPS RK: The effect of celecoxib in familial adenosis polyposis. N. Engl. J. Med. (2000) 342:1946-1952.
69. LANGMAN MJ, JENSON DM, WATSON DW et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAID. JAMA (1999) 282:1929-1933.
70. ROHATGI N, BHATNAGAR A, LOWRY A et al.: Ceavac and idiotype (Anti Id) monoclonal antibody treatment for resected colorectal cancer, Results of a phase II trial. Proc. Am. Sec. Clin. Oncol. (2001):271a (Abstract #1080).
71. MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study of a diversified prime and boost vaccination protocol using recombinant vaccina virus and recombinant non-replicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18:3964-3973.
72. MARSHALL JL, TSANG K, ARLEN P et al.: Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF and IL-2 to the combination of vaccina CEA and alvac CEA administered as a prime and boost in patients with advanced CEA bearing cancers. Proc. Am. Soc. Clin. Oncol. (2001) 1087.
73. MORSE MA, DENG Y, CLOEMAN D et al.: Dendritic cells. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1) pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. (1999) 5:1331-1338.
74. HANNA MG, HOOVER HC, VERMOEKEN JB et al.: Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumour cell vaccine: first randomised controlled trials show promise. Vaccine (2001) 19:2576-2582.
75. PUNT C, NAGY A, DOUILLAND JY et al.: Edrecolomab (17-IA Antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer. Proc. Am. Soc. Clin. Oncol. (2001) 487.